Physician
Med-Ped Health Care LLC
Med-Ped Health Care LLC was paid $1.14M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 38% of everything it billed.
33Billing provider infoMED-PED HEALTH CARE LLC
BERWYN HEIGHTS, MD 20740
BERWYN HEIGHTS, MD 20740
33aNPI1336296730assigned 01/05/2007
33bProvider typeCardiovascular Disease Physician
28Total paid$1.14M
24GClaims48,129
24DCodes billed78
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiovascular Disease Physician providers in Maryland
Rank by total paid#7 of 78
Median peer was paid$37K
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 983 | $15K | |
| 2019 | 1,129 | $8K | |
| 2020 | 19,066 | $539K | |
| 2021 | 10,596 | $214K | |
| 2022 | 5,750 | $153K | |
| 2023 | 7,027 | $105K | |
| 2024incomplete | 3,578 | $109K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 38% | 6,343 | 4,843 | $437K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 30% | 5,675 | 4,292 | $339K |
| 92552 | 3.1% | 1,617 | 1,452 | $36K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.7% | 255 | 245 | $31K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.4% | 245 | 242 | $27K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.4% | 250 | 238 | $27K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.4% | 645 | 537 | $27K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 2.3% | 235 | 210 | $26K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 274 | 169 | $20K |
| 94760 | 1.5% | 9,661 | 7,360 | $17K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.2% | 443 | 329 | $14K |
| 99000 | <1% | 4,607 | 3,614 | $11K |
66 more codes
| 93000 | <1% | 779 | $11K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,745 | $9K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 71 | $9K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 63 | $8K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 88 | $8K |
| 90686 | <1% | 366 | $8K | |
| 99058 | <1% | 821 | $7K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 765 | $6K |
| 96127 | <1% | 1,018 | $4K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 318 | $4K |
| 99173 | <1% | 1,660 | $4K | |
| 99050 | <1% | 291 | $3K | |
| 81025 | <1% | 554 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 176 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 171 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 318 | $3K |
| 81003 | <1% | 1,748 | $3K | |
| 99051 | <1% | 505 | $2K | |
| 86580 | <1% | 300 | $2K | |
| 90647 | <1% | 88 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 37 | $2K |
| 90670 | <1% | 80 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 141 | $2K |
| 90734 | <1% | 76 | $1K | |
| 87563 | <1% | 106 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 29 | $1K |
| 87430 | <1% | 105 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 15 | $1K |
| 80061 | Lipid panel | <1% | 123 | $1K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 58 | $1K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 190 | $1K |
| 83655 | <1% | 89 | $1K | |
| 90723 | <1% | 45 | $944.70 | |
| 80053 | Comprehensive metabolic panel | <1% | 137 | $936.45 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 94 | $867.90 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 129 | $740.43 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 151 | $706.44 |
| 90633 | <1% | 30 | $663.73 | |
| 96160 | <1% | 279 | $637.08 | |
| 90651 | <1% | 31 | $628.56 | |
| 90710 | <1% | 27 | $582.00 | |
| 86803 | <1% | 64 | $554.40 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 65 | $518.88 |
| 36410 | <1% | 55 | $506.61 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 33 | $485.24 |
| 97803 | <1% | 37 | $447.95 | |
| 90715 | <1% | 18 | $425.98 | |
| 86317 | <1% | 49 | $361.86 | |
| 99408 | <1% | 125 | $343.00 | |
| 83721 | <1% | 53 | $322.34 | |
| 84436 | <1% | 82 | $322.14 | |
| 87341 | <1% | 49 | $310.26 | |
| 84479 | <1% | 82 | $303.02 | |
| 90658 | <1% | 13 | $279.36 | |
| 90680 | <1% | 16 | $256.08 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 14 | $246.27 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15 | $194.54 |
| 84550 | <1% | 56 | $167.80 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 26 | $120.06 |
| 92551 | <1% | 22 | $107.89 | |
| 83540 | <1% | 49 | $93.38 | |
| 99442 | <1% | 46 | $39.00 | |
| 99401 | <1% | 15 | $25.50 | |
| 99441 | <1% | 50 | $13.50 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 16 | $0.56 |
| 0353U | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFADUL, JAMAL (MEDICAL DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Express Healthcare, LLC | Berwyn Heights, MD | $6.68M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.